Fareed Kureshy, president and CEO of AutoGenomics, said: “The FDA recently re- labeled warfarin stating that genetic testing may help optimize the use of the drug and lower the risk of bleeding complications. Several of our customers are awaiting such clearance to implement testing in their practice.”